IRVINE, Calif.– With offshore supply chains strained by rising costs and frequent delays, California-based Zymo Research is positioning itself as a dependable domestic alternative for research and diagnostic companies across the U.S.
Backed by more than 30 years of experience, Zymo Research offers a comprehensive range of customizable, U.S.-made products and services—from sample collection and nucleic acid purification to next-generation sequencing (NGS) prep, reagents, and bioinformatics support. All operations are managed from its headquarters in Irvine, enabling the company to maintain tight control over manufacturing, inventory, and fulfillment.
“Zymo Research has spent decades investing in the infrastructure and talent needed to keep innovation and supply in-house,” said Dr. Marc Van Eden, Vice President of Corporate Development. “In a time when long lead times and backorders are the norm, we’re focused on delivering what our clients need—quickly and reliably.”
The company’s vertically integrated capabilities range from OEM and private-label manufacturing to custom product development, formulation, and even injection molding for plastics. Zymo also provides widely used recombinant enzymes, including Proteinase K, DNase I, and RNase A, for both clinical and research applications.
At a time when offshore bottlenecks continue to disrupt laboratory workflows, Zymo’s domestic-first model provides a rare level of supply chain stability and customer responsiveness.
“Customer service isn’t a department here—it’s a core value,” added Van Eden. “We pride ourselves on real people delivering real solutions.”
As global logistics evolve, Zymo Research is reaffirming its commitment to flexibility and collaboration, offering high-quality scientific tools “Made in California, delivered worldwide, and trusted by scientists.”
